Maze Therapeutics (NASDAQ:MAZE) Hits New 52-Week Low – Should You Sell?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price reached a new 52-week low during trading on Monday . The company traded as low as $9.88 and last traded at $11.49, with a volume of 13183 shares traded. The stock had previously closed at $10.99.

Analysts Set New Price Targets

A number of brokerages have weighed in on MAZE. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Guggenheim started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set a “buy” rating and a $19.00 target price for the company. Leerink Partners assumed coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 price target on the stock. JPMorgan Chase & Co. began coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price target on the stock. Finally, Leerink Partnrs upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and a consensus target price of $25.67.

Maze Therapeutics Stock Performance

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.